Schwarz Pharma, a subsidiary of UCB, submitted a MAA to the EMEA for Vimpat to treat diabetic neuropathic pain and it has been accepted for review. Vimpat is an anticonvulsant drug with a novel dual mode of action acting on CRMP-2 (collapsing response mediator protein 2) and sodium channel slow inactivation. Diabetic neuropathic pain is a common chronic pain syndrome from which approximately eleven million people with diabetes suffer. Neuropathic pain is caused by damage to a peripheral o...